Vimarsana
Biggest News Aggregation in the World

Fred Locke News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Fred Locke. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Fred Locke Today - Breaking & Trending Today

How Does Metabolic Tumor Volume Affect Responses to Axi-Cel in LBCL? - Vimarsana News

How Does Metabolic Tumor Volume Affect Responses to Axi-Cel in LBCL?

The authors say a standard method of assessing metabolic tumor volume would be needed for its use to become widespread.

Source: ajmc.com
KITE TO PRESENT NEW CAR T-CELL THERAPY DATA ACROSS MULTIPLE INDICATIONS AND MANUFACTURING EXPERIENCE AT EBMT 2023 - Vimarsana News

KITE TO PRESENT NEW CAR T-CELL THERAPY DATA ACROSS MULTIPLE INDICATIONS AND MANUFACTURING EXPERIENCE AT EBMT 2023

KITE TO PRESENT NEW CAR T-CELL THERAPY DATA ACROSS MULTIPLE INDICATIONS AND MANUFACTURING EXPERIENCE AT EBMT 2023  Stockley Park, UK – 19 April 2023 – Kite, a Gilead Company, will support eight data presentations, including updated findings in multiple indications across its portfolio of two CAR T-c...

Dennis Norton, obituary - Vimarsana News

Dennis Norton, obituary

ROCKPORT — Dennis E. Norton, 71, passed away with the love of his life, Doris, by his side on December 6, 2022, on the beautiful island of Maui. Dennis was seriously injured November 25 while on vacation with his loving family. Born in Skowhegan,...

Kite, a Gilead Company, presents long-term CAR T cell therapy data in lymphomas at the 48th EBMT Annual Meeting - Vimarsana News

Kite, a Gilead Company, presents long-term CAR T cell therapy data in lymphomas at the 48th EBMT Annual Meeting

Kite, a Gilead Company, presents long-term CAR T cell therapy data in lymphomas at the 48th EBMT Annual Meeting Primary analysis of pivotal data on earlier use of CAR T cell therapy as second-line treatment in relapsed/refractory diffuse large B cell lymphomaLong-term overall survival and safety management data...

Is Second-Line Axi-Cel the New Standard in Aggressive B-Cell Lymphoma? - Vimarsana News

Is Second-Line Axi-Cel the New Standard in Aggressive B-Cell Lymphoma?

Ian Flinn, MD, leads a roundtable discussion with Loretta Nastoupil, MD, and Amitkumar Mehta, MD